share_log

HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Lowers Price Target to $18

Benzinga ·  Oct 12, 2023 07:06

HC Wainwright & Co. analyst Joseph Pantginis maintains Astria Therapeutics (NASDAQ:ATXS) with a Buy and lowers the price target from $20 to $18.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment